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Long non-coding RNAs (lncRNAs) are important regulators of gene expression that influ-
ence almost every step in the life cycle of genes, from transcription to mRNA splicing, RNA
decay, and translation. Besides their participation to normal physiology, lncRNA expres-
sion and function have been already associated to cancer development and progression.
Here, we review the functional role and mechanisms of action of lncRNAs in normal
hematopoiesis and how their misregulation may be implicated in the development of blood
cell cancer, such as leukemia.
Keywords: lncRNA, leukemia, cancer, hematopoiesis, blood cells
INTRODUCTION
In the last decade, the family of regulatory RNAs has undergone
a sudden expansion with the discovery and the functional charac-
terization of long non-coding RNAs (lncRNAs). LncRNAs gener-
ally indicate ribonucleic molecules longer than 200 nucleotides
without defined open reading frames. To date, the number of
human lncRNAs is in the range of ~10,000 transcripts and, for
some of them, the involvement in important regulatory circuits
of gene expression has been identified (1). However, the majority
of lncRNAs remains uncharacterized, and the actual proportion
of lncRNAs that might have biological function is hotly debated.
LncRNAs are usually classified by their position relative to cod-
ing genes and are usually defined as sense, antisense, or intronic,
if they overlap with another transcript, bidirectional when their
transcription is initiated in close proximity and opposite ori-
entation to a neighboring coding transcript, and intergenic or
intervening (known as lincRNAs) if they lie between two genes.
In addition, lncRNAs can be also produced from enhancer or
promoter regions, known as eRNAs and pRNAs (or PROMPTs),
respectively. LncRNAs may act by different mechanisms in both
nuclear and cytoplasmic compartments (Figure 1). In particular,
they can influence many cellular processes such as spatial con-
formation of chromosomes, chromatin and DNA modifications,
RNA transcription, pre-mRNA splicing, mRNA degradation, and
mRNA translation (2). Furthermore, few of them can also produce
small biological active peptides (3).
In the last few years, a large amount of sequence data have been
generated, which allowed the identification of thousands of lncR-
NAs expressed in different cell types and stages of development
(4). Different studies have already shown that changes in lncRNA
expression may contribute to the development and progression of
human diseases, including cancer. Here, we review the role of lncR-
NAs in normal and malignant hematopoiesis, with an emphasis on
leukemia, and discuss expectations and challenges in using these
RNA molecules as biomarkers and therapeutic targets in leukemia.
LONG NON-CODING RNAs IN NORMAL HEMATOPOIESIS
Several lncRNAs have been already found in the development of
blood cells, even if the majority has not yet been functionally
characterized. One of the first to be identified was the Eosinophil
Granule Ontogeny lncRNA EGO (5). This non-coding transcript
was identified in eosinophil differentiation of CD34+ hematopoi-
etic progenitor cells, where it stimulates differentiation and mature
cell function by regulating eosinophil granule protein expression
at the transcription level (5). However, its mode of action has not
been described yet. Subsequently, it was discovered “antisense to
PU.1,” a lncRNA, which is antisense to the master hematopoietic
transcriptional factor PU.1 and that negatively regulates its expres-
sion (6). Generally, PU.1 expression levels are critical for normal
hematopoietic development and suppression of leukemia. Accord-
ing to their model, the author suggested that “antisense to PU.1,”
lncRNA would keep PU.1 expression levels from being too high
by negatively regulating PU.1 mRNA translation. Notably, even
though the precise mechanism of action was not characterized,
this was one of the first demonstrations of antisense lncRNA act-
ing in the cytoplasm by inhibiting translation. The advent of the
first lncRNA catalogs produced by the FANTOM and ENCODE
international research consortiums and the development of high-
throughput technologies for measuring lncRNAs expression have
produced a great boost to the identification of lncRNA from var-
ious cell types, including blood cells. HOTAIRM1 was identified
by microarray analysis as one of the lncRNAs induced during all-
trans retinoid acid (ATRA)-mediated granulocytic differentiation
of APL cell lines (7). This lncRNA is one of the numerous lncRNAs
produced from the HOXA cluster and its knockdown attenuated
the expression of different HOXA genes, which are important tran-
scriptional regulators of normal and malignant hematopoiesis.
HOTAIRM1 modulates the levels of several granulocytic differ-
entiation genes (7, 8) and a delay in ATRA-induced granulocytic
differentiation was reported upon HOTAIRM1 knockdown (8).
Also in this case, the molecular mechanism of HATAIRM1 action
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FIGURE 1 | Models of lncRNA functions. Nuclear lncRNAs can regulate
transcription by acting as enhancer RNA (eRNA) (A), by recruiting
chromatin modifying complexes (B), or by regulating transcription factors
activity (C). Moreover, they can regulate gene expression by acting on the
spatial conformation of chromosomes (D) or by influencing pre-mRNA
splicing (E). Cytoplasmic lncRNAs can regulate mRNA expression by
regulating mRNA stability (F), mRNA translation (G), or by competing for
microRNA binding (H). In addition, few lncRNAs contain small open
reading frames (ORFs) that can be translated in biological active small
peptides (I).
is still not known. In 2011, Hu and colleagues report the identifica-
tion by RNA-sequencing of the “Erythroid ProSurvival lincRNA”
(lincRNA-EPS) between about 400 lncRNAs whose expression is
modulated during mouse erythroid differentiation (9). LincRNA-
EPS promotes terminal differentiation and inhibits apoptosis of
mature erythrocytes by inhibiting the pro-apoptotic gene Picard
expression through a still not defined mechanism (9). A sec-
ond high-throughput study by RNA-seq in murine erythropoiesis
identified 132 novel lncRNAs with erythroid-restricted expression,
many of which are targeted by key erythroid transcription fac-
tors (10). Knockdown of 12 of these lncRNAs severely impaired
erythroid maturation, suggesting important regulatory functions.
One of them is produced from an enhancer region of the BAND3
gene, the major anion transporter of the red cell membrane, and
is required for its transcriptional activation acting, very likely,
as an enhancer RNA (eRNA) (10). A similar study was per-
formed on mouse erythroblasts, megakaryocytes, megakaryocyte-
erythroid precursors, and human erythroblasts (11). In particular,
the authors identified several lncRNAs specific for each cell type,
many of them regulated by key hematopoietic transcription fac-
tors including GATA1 and TAL1. By knocking down 21 of the
most abundant murine lncRNAs, they showed that,despite the lack
of conservation, 7 of them were required for erythroid terminal
differentiation. Furthermore, four of the functional lncRNAs were
also found by the independent study of Alvarez-Dominguez et al.
(see above). Notably, the majority of the identified lncRNAs were
not conserved in human erythroblasts. The general low conser-
vation of lncRNAs may be due to the fact that their tertiary
structure is more important than the primary sequence if com-
pared with protein-coding RNAs. Indeed, many lncRNAs function
as platform for the assembly of macromolecular complexes (1, 12).
Profiling of lncRNA expression during differentiation of mono-
cytes into dendritic cells (DCs) identified lnc-DC (13). Lnc-DC is
a cytoplasmic lncRNA that acts by activating the transcription fac-
tor STAT3, which is required for DCs differentiation. In particular,
lnc-DC directly binds STAT3 and maintains its active phospho-
rylated form by blocking its dephosphorylation by Src homology
region 2 domain-containing phosphatase-1 (SHP-1).
Emerging data have identified an important contribution of
lncRNAs to the development and function of adaptive immune
cells. Microarray analysis on purified human and mouse CD8+
T-cells identified 29 lncRNAs specific for these lymphocytes, and,
more importantly, 21 out of them were modulated during memory
T-cell differentiation, 81 during lymphocyte activation, and 4 dur-
ing both transitions. A more comprehensive analysis of lncRNA
expression during T-cell development was performed from 42
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different T-cell types at various developmental and differentiation
stages by using RNA-seq (14). This study identified 1,524 genomic
regions expressing lncRNAs that are much more specific for lineage
or developmental stage compared to mRNAs. T-cell-specific tran-
scription factors, such as T-bet, STAT4, GATA-3, and STAT6, were
shown to be largely involved in the specific expression of the iden-
tified lincRNAs in different T-cells lineages. Furthermore, many
lncRNAs are adjacent to genes encoding proteins critical to T-cell
function. One of them, LincR-Ccr2-5’AS, controls the expression
of several chemokine receptors and, eventually, the migration of
T-cells. However, also in this case the mechanism of action was not
identified. More recently, a second study performed a lncRNA pro-
filing in human T- and B-lymphocytes at different differentiation
stages by RNA-seq and identified over 500 previously unknown
lncRNAs (15). One of them, linc-MAF4, regulates the expression
of MAF,a transcription factor required for T-cell function, through
the recruitment of chromatin modifiers.
LncRNAs are also involved in the regulation of the innate
immune and inflammatory responses, as reviewed in detail
elsewhere (16).
LONG NON-CODING RNAs IN LEUKEMIA
Defects in cell differentiation and uncontrolled proliferation are a
hallmark of leukemia. Thus, every lncRNA that is involved in gene
expression control during the development of blood cells, if dereg-
ulated, might contribute to the development and the progression
of cancer. Since their discovery, lncRNAs have been profiled by
various tumor types, including leukemia and other hematopoietic
malignancies. Moreover, lncRNA expression has been already cor-
related with diagnostic and prognostic factors. However, only few
lncRNAs have been directly involved in the tumorigenic processes
of blood cell cancers.
Human T cell acute lymphoblastic leukemia (T-ALL) is gener-
ally characterized by mutations that activate the NOTCH1 signal-
ing (17). The lncRNA LUNAR1 (leukemia-induced non-coding
activator RNA) is a NOTCH-regulated oncogenic lncRNA in T-
ALL (18) that promotes T-ALL cell growth due to its ability to
enhance IGF1R mRNA expression and sustains IGF1 signaling.
In particular, LUNAR1 acts as eRNA by recruiting the mediator
complex on the IGF1R promoter to activate, eventually, its tran-
scription. Notably, T-ALL cells with lower LUNAR1 levels showed
a significant loss of proliferation potential in xenograft assay (18).
A microarray analysis of lncRNAs from chronic myeloid
leukemia (CML) with Bcr–Abl translocation identified the Beta
Globin Locus 3 (BGL3) lncRNA (19). This lncRNA positively
regulates the level of the tumor suppressor PTEN by acting as
a competing endogenous RNA (ceRNA) (20). Notably, lncRNA-
BGL3 expression decreased the survival of Bcr–Abl-positive K562
leukemic cells and stimulated the apoptosis induced by imatinib,
a tyrosine kinase inhibitor used in the treatment of Bcr–Abl CML.
Moreover, its expression affected Bcr–Abl-induced tumorigenesis
in xenograft mouse model (19). Another relevant lncRNA in Bcr–
Abl CML is the imprinted H19 lncRNA, which plays important
roles in embryonal development and growth control (21). This
lncRNA was found upregulated in many different cancers, includ-
ing Bcr–Abl CML, and predicted to be an oncogenic lncRNA.
Moreover, in Bcl–Abl CML cells, H19 is positively regulated by the
oncogene c-Myc (21). Down-regulation of H19 levels affected cell
proliferation and attenuated tumor formation in xenograft assay
(21). Notably, in muscle cells and different solid tumors, H19 has
been shown to inhibit the oncosuppressor let-7 microRNA family,
thus acting as a ceRNA (22–24). Since microRNAs play an impor-
tant role in blood cell development and leukemia, it is easy to
predict that, in the future, other lncRNAs regulating microRNA
function in the blood system will be identified.
Another lncRNA involved in acute myeloid leukemia (AML) is
IRAIN (25), which is produced from the insulin-like growth factor
type I receptor (IGF1R) imprinted locus. Aberrant expression of
IGF1R promotes AML cell growth through the PI3K/Akt signaling
pathway. IRAIN is transcribed antisense to IGF1R and is involved
in the formation of a long-range intrachromosomal interaction
between the IGF1R promoter and a distant intragenic enhancer
(25). Moreover, IRAIN is down-regulated in leukemia cell lines
and in patients with high-risk AML.
The well-known X-inactive specific transcript Xist lncRNA,
an important regulator of X-chromosome inactivation in mam-
mals, is aberrantly expressed in different human cancer, includ-
ing leukemia (26). Xist provided one of the first examples of
an lncRNA that is directly involved in the formation of repres-
sive chromatin and in addition to dosage compensation it may
also have an important role in cell differentiation. In mouse
hematopoietic stem cells, both the homozygous and heterozy-
gous conditional deletion of Xist resulted in the development
of blood cell cancers and in accelerated death, further suggest-
ing that alteration in the X inactivation process contributes to
tumorigenesis (27).
Long non-coding RNAs have been profiled from patients with
citogenetically normal (CN) AML (28). Distinctive lncRNA pro-
files were found to be associated with specific mutations, such as
mutations in the NPM1,CEBPA,IDH2,ASXL1,and RUNX1 genes,
and internal tandem duplications in the FLT3 gene (FLT3-ITD).
More importantly, lncRNA expression correlated with treatment
response and survival (28). One of the lncRNA that is specifically
upregulated in (CN) AML with CEBPA mutation is the onco-
genic urothelial carcinoma-associated 1 lncRNA (UCA1). UCA1
was found upregulated in different solid tumors and its down-
regulation affects proliferation of AML cells (29). An lncRNA
profiling was also performed in B-acute lymphoblastic leukemia
(B-ALL) (30). Also in B-ALL, lncRNA expression correlated with
cytogenetic abnormalities and survivals of B-ALL patients. More-
over, the lncRNA B-ALL-associated long RNAs-2 (BARL-2) was
identified as a modulator of the response to corticosteroid treat-
ment, which is used in B-ALL therapy. Therein, these studies
suggest that, similarly to microRNAs, lncRNAs might be utilized
as diagnostic and prognostic markers in leukemia.
CONCLUSION
In the next future, we will witness a comprehensive identifica-
tion and functional analyzes of lncRNAs expressed during all
stages of hematopoiesis and in multiple species, which will con-
tribute to better defining the role of these molecules in blood cell
development. Thus, it seems safe to predict that many new func-
tional lncRNAs will be identified. Furthermore, lncRNAs might
have diagnostic applications, with changes in their expression
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already associated with different classes of leukemia, regardless
of function.
It is very likely that the established molecular circuitries known
to control blood cell differentiation will need to be reevaluated in
the light of the contribution of this complex class of non-coding
transcripts. However, the identification of functional molecules
and, above all, the mechanisms by which they can regulate gene
expression is still challenging for the field. Many lncRNAs, espe-
cially those acting in cis, are present in only few copies per cell and
might not be considered in functional studies. Moreover, different
functions might be active in different cells and at different devel-
opmental stages. LncRNAs can be very long, even several thousand
nucleotides, which fold in complex three-dimensional structures
to act as molecular scaffolds. Indeed, a single lncRNA molecule
might carry out a large number of functions within the cells by
interacting and cooperate with different cell-specific interactors
(both proteins and nucleic acids) or by localizing in specific com-
partments. A large amount of sequence data have been generated
in last few years, which already allowed the identification of thou-
sands of lncRNAs expressed in different stages of hematopoietic
development but most studies merely identify functional lncRNAs
without explaining how these molecules act within the cell. This
has further generated the need to develop new experimental tools
to identify and analyze lncRNA mechanisms of action. Further-
more, targeted deletion studies in primary cells, or animal models
when applicable, will be necessary to assess the specific functions
of lncRNAs involved in normal and malignant hematopoiesis.
Another important aspect to consider is the fact that, despite
the advantages of RNA-seq in terms of sensitivity and accessibility,
the assembly of transcript models from short reads is still lim-
ited and the bioinformatic tools utilized often provide different
outcomes from same raw data. Therein, the lists of lncRNAs iden-
tified in different studies from the same cell type do not always
coincide. In the next future, the development of technologies for
long reads sequencing that minimize the bioinformatic assembly
of novel transcripts will be of great help to standardize and unify
the many different existing lists of lncRNAs.
In conclusion, similarly to the most famous microRNAs, lncR-
NAs will become subject of several studies in normal and malig-
nant hematopoiesis that, hopefully, will help to determine the
therapeutic significance of lncRNAs in leukemia.
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